Shafqat Inam

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: April 06, 2026

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: April 06, 2026

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

Journal: Transplantation and cellular therapy

Published: March 10, 2026

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

Journal: Transplantation and cellular therapy

Published: February 22, 2026

A Computerized Cognitive Test for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Pilot Study.

A Computerized Cognitive Test for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Pilot Study.

Journal: Transplantation and cellular therapy

Published: December 22, 2025

Post-Transplantation Cyclophosphamide Dosed by Total Body Weight Leads to Delay of Platelet Engraftment in Obese Patients.

Post-Transplantation Cyclophosphamide Dosed by Total Body Weight Leads to Delay of Platelet Engraftment in Obese Patients.

Journal: Transplantation and cellular therapy

Published: December 18, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood

Published: November 04, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood

Published: November 04, 2025

Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy.

Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy.

Journal: Transplantation and cellular therapy

Published: October 30, 2025

Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy.

Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy.

Journal: Transplantation and cellular therapy

Published: October 06, 2025

Neurotoxicity associated with chimeric antigen receptor T-cell therapy.

Neurotoxicity associated with chimeric antigen receptor T-cell therapy.

Journal: Journal of neuroimmunology

Published: March 21, 2025

CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.

CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.

Journal: British journal of haematology

Published: February 24, 2025

Showing 1-12 of 27

Last Updated: 09/26/2026